AptaBio Therapeutics Inc Cash Flow Conversion Efficiency
AptaBio Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has a cash flow conversion efficiency ratio of -0.061x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.73 Billion ≈ $-1.85 Million USD) by net assets (₩44.61 Billion ≈ $30.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AptaBio Therapeutics Inc (293780) total market value for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of AptaBio Therapeutics Inc (2017–2024)
Cash flow conversion efficiency of AptaBio Therapeutics Inc from 2017 to 2024. This chart illustrates how AptaBio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AptaBio Therapeutics Inc share price for real-time trading data and today's change.
AptaBio Therapeutics Inc Cash Flow Conversion Ratio Explained
AptaBio Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AptaBio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AptaBio Therapeutics Inc ranked by their cash flow conversion efficiency. Review how financially flexible is AptaBio Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korea Fuel-Tech Corporation
KQ:123410
|
0.066x |
|
Shanghai Bailian Group Co Ltd B
SHG:900923
|
-0.046x |
|
51 TALK ONL. SP.ADR A 60
F:C4G0
|
N/A |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
0.386x |
|
Kingwaytek Technology Co Ltd
TWO:6516
|
-0.016x |
|
Bank Qnb Indonesia Tbk
JK:BKSW
|
-0.021x |
|
Chung Fu Tex-International Corp
TW:1435
|
-0.010x |
|
IL Science Co. Ltd
KQ:307180
|
0.100x |
Annual Cash Flow Conversion Efficiency for AptaBio Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of AptaBio Therapeutics Inc from 2017 to 2024. Also see balance sheet size of AptaBio Therapeutics Inc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩54.20 Billion ≈ $36.73 Million |
₩-12.16 Billion ≈ $-8.24 Million |
-0.224x | +2.32% |
| 2023-12-31 | ₩61.36 Billion ≈ $41.59 Million |
₩-14.10 Billion ≈ $-9.55 Million |
-0.230x | -76.05% |
| 2022-12-31 | ₩52.37 Billion ≈ $35.49 Million |
₩-6.83 Billion ≈ $-4.63 Million |
-0.130x | +9.57% |
| 2021-12-31 | ₩61.67 Billion ≈ $41.79 Million |
₩-8.90 Billion ≈ $-6.03 Million |
-0.144x | -174.59% |
| 2020-12-31 | ₩72.04 Billion ≈ $48.82 Million |
₩-3.79 Billion ≈ $-2.57 Million |
-0.053x | +34.20% |
| 2019-12-31 | ₩75.16 Billion ≈ $50.93 Million |
₩-6.00 Billion ≈ $-4.07 Million |
-0.080x | +16.38% |
| 2018-12-31 | ₩18.31 Billion ≈ $12.41 Million |
₩-1.75 Billion ≈ $-1.19 Million |
-0.095x | -268.19% |
| 2017-12-31 | ₩-31.54 Billion ≈ $-21.37 Million |
₩-1.79 Billion ≈ $-1.21 Million |
0.057x | -- |
About AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more